Indian Pharma Stocks Rise Amid Global Currency Shifts
Pharmaceutical equities in India advanced on Wednesday, supported by solid corporate earnings and a depreciating rupee. This occurred as broader market indices, Sensex and Nifty, recorded declines.
Market Performance and Currency Depreciation
The Nifty Pharma index recovered from early losses to increase by nearly 1 percent, surpassing the 25,000 threshold. The index reached a 52-week high of 25,043 during early trading before moderating slightly.
The Indian currency declined to 96.96 against the dollar, exceeding its previous all-time low of 96.6150. The currency has depreciated by 6 percent since the onset of the Iran war in late February. A weaker rupee generally benefits export-oriented sectors such as pharmaceuticals.
Corporate Earnings Drive Sector Growth
Zydus Lifesciences led the gains, with shares increasing over 7 percent to a 52-week high of 1,091 rupees. This followed a report of a 9 percent year-on-year rise in consolidated net profit, reaching 1,272.5 crore rupees for the January-March quarter. Revenue increased by more than 16 percent to 7,587 crore rupees. The company also announced a share buyback valued at 1,100 crore rupees and a final dividend.
Mankind Pharma shares advanced by over 3 percent. The company reported a 32 percent year-on-year increase in consolidated net profit to 554 crore rupees, with revenue rising 12 percent to 3,443 crore rupees.
Laurus Labs, Aurobindo Pharma, and Biocon saw modest gains, alongside marginal increases for Lupin, Sun Pharma, Cipla, Torrent Pharma, and Divi's Laboratories. Conversely, Ajanta Pharma, Piramal Pharma, Gland Pharma, Dr Reddy's Labs, Abbot India, Glenmark, Alkem Labs, and IPCA Labs experienced minor declines.
Technical Outlook and Structural Stability
Harshal Dasani, Business Head at INVasset PMS, noted that the sector's technical structure remains constructive despite global pressures. He stated that capital is shifting toward sectors with reliable earnings visibility rather than mere momentum.
The index shows a higher-high, higher-low pattern, with immediate support at 24,700 to 24,800. A stronger support level sits near 24,400. Mr. Dasani advised that broader market participation is necessary to sustain the upward trend, noting that controlled pullbacks offer a more stable entry point than vertical rallies.